...
首页> 外文期刊>Medicine. >Evidence for Chronic Kidney Disease-Mineral and Bone Disorder Associated With Metabolic Pathway Changes
【24h】

Evidence for Chronic Kidney Disease-Mineral and Bone Disorder Associated With Metabolic Pathway Changes

机译:与代谢途径改变相关的慢性肾脏疾病-矿物质和骨疾病的证据

获取原文
获取原文并翻译 | 示例

摘要

Abnormalities in the levels of calcium, phosphorus, and parathyroid hormone (PTH) in serum are typical for patients with chronic kidney disease (CKD). They are used routinely to predict the onset of CKD-mineral and bone disorder (MBD). However, CKD-MBD associated with metabolic pathway imbalance is not well understood.The objective of the study was to identify endogenous metabolic signatures in patients with intact PTH using mass spectrometry-based metabolomics. This study was a cross-sectional study. Ultra performance liquid chromatography-Quadrupole Time-of-Flight/mass spectrometry-based metabolic profiling was employed to analyze serum samples from 19 disease controls (DCs) (intact parathyroid hormone [iPTH] 150-300pg/mL) and 19 secondary hyperparathyroidism (SHPT) patients (iPTH >300pg/mL) (the training data set) to identify metabolic biomarkers for CKD-MBD. Then, another set of samples including 19 DCs (iPTH 150-300pg/mL) and 19 SHPT patients (iPTH >300pg/mL) (the test data set) were used to validate the potential biomarkers identified.Metabolic profiling analyses revealed different patterns of endogenous metabolites between the SHPT and the DC groups. A total of 32 unique metabolites were identified and 30 metabolites were elevated in the iPTH compared with control serum pools. Cytidine and l-phenylalanine were downregulated in the SHPT patients. The metabolic signatures identified were assessed respectively by an internal 10-fold cross validation with an accuracy of 91.4% and an external validation with an accuracy of 71.1%, a sensitivity of 73.7%, and a specificity of 68.4%.Mass spectrometry-based metabolomic analyses for SHPT patients promises immense potential for early diagnosis and therapy monitoring. Our results indicated that the onset of CKD-MBD is associated with pathway changes of protein synthesis and metabolism, amino acid metabolism, energy metabolism, and steroid hormone metabolism, with obvious promise for better understanding the pathogenesis of this disease. Several metabolic biomarkers were identified, which warrant further development.
机译:慢性肾脏病(CKD)患者的血清钙,磷和甲状旁腺激素(PTH)水平异常。它们通常用于预测CKD矿物和骨骼疾病(MBD)的发作。然而,与代谢途径失衡相关的CKD-MBD尚不十分清楚。该研究的目的是使用基于质谱的代谢组学方法确定完整PTH患者的内源性代谢特征。这项研究是横断面研究。采用超高效液相色谱-四极杆飞行时间/质谱法进行代谢谱分析,分析了19个疾病对照(DC)(完整的甲状旁腺激素[iPTH] 150-300pg / mL)和19个继发性甲状旁腺功能亢进症(SHPT)的血清样本)(iPTH> 300pg / mL)(训练数据集)患者,以识别CKD-MBD的代谢生物标志物。然后,使用另一组样品(包括19个DC(iPTH 150-300pg / mL)和19个SHPT患者(iPTH> 300pg / mL)(测试数据集)来验证已鉴定的潜在生物标志物。代谢谱分析揭示了不同的SHPT和DC组之间的内源性代谢产物。与对照血清库相比,iPTH中总共鉴定出32种独特的代谢物,并且升高了30种代谢物。 SHPT患者的胞苷和1-苯丙氨酸被下调。通过内部10倍交叉验证(准确度为91.4%)和外部验证(准确度为71.1%,灵敏度为73.7%,特异性为68.4%)分别评估鉴定出的代谢特征。对SHPT患者的分析有望为早期诊断和治疗监测提供巨大潜力。我们的结果表明,CKD-MBD的发作与蛋白质合成和代谢,氨基酸代谢,能量代谢和类固醇激素代谢的途径改变有关,显然有望更好地了解该病的发病机理。确定了几种代谢生物标志物,这些标志物有待进一步发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号